Dr. Schneider is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1500 E Medical Center Dr
Ann Arbor, MI 48109Phone+1 734-936-4000
Summary
- Dr. Bryan Schneider is an oncologist in Ann Arbor, MI and is affiliated with Michigan Medicine. He received his medical degree from Indiana University School of Medicine and has been in practice 19 years. He specializes in hematologic oncology and is experienced in medical oncology, thoracic oncology, general medical oncology, and lung neoplasms.
Education & Training
University of MichiganFellowship, Hematology and Medical Oncology, 2002 - 2005
Indiana University School of MedicineResidency, Internal Medicine, 1998 - 2002- Indiana University School of MedicineClass of 1998
Certifications & Licensure
MI State Medical License 2002 - 2027
NY State Medical License 2008 - 2016- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Clinical Trials
- 177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors Start of enrollment: 2009 Jul 01
- BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors Start of enrollment: 2013 Oct 01
Publications & Presentations
PubMed
- 222 citationsManagement of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.John A Thompson, Bryan J Schneider, Julie Brahmer, Amaka Achufusi, Philippe Armand
Journal of the National Comprehensive Cancer Network. 2022-04-01 - 639 citationsManagement of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.Bryan J. Schneider, Jarushka Naidoo, Bianca Santomasso, Christina Lacchetti, Sherry Adkins
Journal of Clinical Oncology. 2021-11-01 - 292 citationsNCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.John A. Thompson, Bryan J. Schneider, Julie R. Brahmer, Stephanie Andrews, Philippe Armand
Journal of the National Comprehensive Cancer Network. 2020-03-01
Lectures
- Implications of incidental germline findings identified in the context of clinical whole exome sequencing (WES) for guiding cancer therapy.2019 ASCO Annual Meeting - 6/1/2019
- Review and Interpretation of the 2012 San Antonio Breast Cancer SymposiumIndiana University School of Medicine, Indianapolis, Indiana - 1/19/2013
Press Mentions
Manatt Expands National Health Care Capabilities with Arrival of Prominent Litigator in ChicagoOctober 7th, 2021
ASCO Endorses ASTRO Guideline on Stereotactic Body Radiotherapy for Early-Stage NSCLCNovember 16th, 2017
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
